Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dimerix Limited ( (AU:DXB) ) has issued an update.
Dimerix Limited has announced the details for its 2025 Annual General Meeting (AGM), which will be held in person at its office in Fitzroy, Victoria. The company has made available the Notice of Meeting and Proxy Form online, emphasizing the importance of shareholder engagement and participation in the upcoming meeting. This announcement reflects Dimerix’s commitment to transparency and effective communication with its stakeholders, as it continues to advance its clinical programs and strengthen its position in the biopharmaceutical industry.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, with a particular emphasis on kidney diseases. The company is advancing its proprietary Phase 3 product candidate, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also working on DMX-700 for respiratory disease. These products were identified using Dimerix’s proprietary Receptor Heteromer Investigation Technology (Receptor-HIT), a scalable platform for understanding receptor interactions and identifying new drug opportunities.
Average Trading Volume: 1,523,265
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$312.1M
See more data about DXB stock on TipRanks’ Stock Analysis page.